Foscarnet Sodium and Sodium Chloride Injection

Background:

Foscarnet sodium, a pyrophosphate analog, disrupts viral replication by inhibiting the DNA polymerase enzyme essential for the multiplication of herpesviruses, including cytomegalovirus (CMV) and herpes simplex virus (HSV). The efficacy of this antiviral agent extends to cases where resistance has emerged against other antiviral medications. Its unique mechanism of action positions it as a valuable asset in the therapeutic arsenal against complex viral infections.

The story of Foscarnet Sodium and Sodium Chloride Injection begins with the urgent need for alternative treatments for drug-resistant viral strains. As other antivirals faced challenges posed by resistant viral mutations, researchers sought a resilient solution, leading to the development of foscarnet sodium. This breakthrough marked a paradigm shift in antiviral therapy, offering a lifeline to patients grappling with infections that had previously eluded effective treatment.

The inclusion of sodium chloride in the injection serves a dual purpose – it not only serves as a carrier for foscarnet sodium but also ensures an isotonic solution that is compatible with the body's physiological environment. This thoughtful combination enhances the safety and efficacy of the intravenous administration, allowing for a seamless integration of the Anti-infection Product into the patient's circulatory system.

In the context of HIV/AIDS, where immune defenses are compromised, this antiviral powerhouse plays a crucial role in preventing and treating CMV retinitis, a potentially blinding condition. Additionally, its utility extends to the control of HSV infections in patients with impaired immunity.

The intravenous route of administration offers a swift and direct means of delivering foscarnet sodium to the bloodstream, ensuring rapid onset of antiviral action. This modality is particularly advantageous in critically ill patients or those unable to tolerate oral medications. The intravenous formulation allows for precise dosing, a critical factor in achieving therapeutic efficacy while minimizing the risk of adverse effects.

Safety considerations loom large in the landscape of pharmaceutical interventions, and Foscarnet Sodium and Sodium Chloride Injection undergoes rigorous scrutiny. Close monitoring of electrolyte levels, especially calcium, is imperative, given foscarnet sodium's potential to chelate minerals. Healthcare providers navigate this delicate balance, tailoring treatment regimens to individual patient needs while mitigating the risk of electrolyte imbalances.

Antiviral Product-Foscarnet Sodium and Sodium Chloride Injection

Intravenous drip. Dose individualization. Central intravenous infusion: (injection 24mg/ml) can be used directly without dilution. Peripheral intravenous infusion: Must be diluted with 5% glucose or saline to 12mg/ml before use. 1. Cytomegalovirus retinitis in patients with AIDS (normal renal function). Induction therapy: The recommended initial dose is 60mg/kg, once every 8 hours, the duration of infusion should not be less than 1 hour, and the therapy should be used for 2-3 weeks according to the efficacy. Maintenance treatment: The maintenance dose was 90 ~ 120mg/kg per day (adjusted according to renal function), and the duration of infusion should not be less than 2 hours. During maintenance therapy, if the condition worsens, induction therapy and maintenance therapy can be repeated. 2. Patients with immune impairment were resistant to acyclovir herpes simplex virus (HSV) skin mucosal infection. The recommended dose is 40mg/kg, once every 8 or 12 hours, and the duration of infusion should not be less than 1 hour, for 2 to 3 weeks or until cure.